Have a personal or library account? Click to login
The Phosphodiesterase-5 Inhibitors and Prostate Cancer – What We Rely Know About It? Cover

The Phosphodiesterase-5 Inhibitors and Prostate Cancer – What We Rely Know About It?

EABR. Experimental and Applied Biomedical Research
Volume 23 (2022): Issue 2 (June 2022)
By: Dejan Simic,  Aleksandar Spasic,  Mirko Jovanovic,  Predrag Maric,  Radovan Milosevic and  Ivan Srejovic  
Open Access
|Jul 2022

Authors

Dejan Simic

Clinic of Urology, Military Medical Academy, Belgrade, Serbia

Aleksandar Spasic

Clinic of Urology, Military Medical Academy, Belgrade, Serbia

Mirko Jovanovic

Clinic of Urology, Military Medical Academy, Belgrade, Serbia

Predrag Maric

Clinic of Urology, Military Medical Academy, Belgrade, Serbia

Radovan Milosevic

Clinic of Urology, Military Medical Academy, Belgrade, Serbia

Ivan Srejovic

University of Kragujevac, Faculty of Medical Sciences, Department of Physiology, Kragujevac, Serbia
DOI: https://doi.org/10.1515/sjecr-2017-0073 | Journal eISSN: 2956-2090 | Journal ISSN: 2956-0454
Journal RSS Feed
Language: English
Page range: 175 - 184
Submitted on: Dec 19, 2017
|
Accepted on: Dec 28, 2017
|
Published on: Jul 11, 2022
Published by: University of Kragujevac, Faculty of Medical Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Phosphodiesterase-5 inhibitors,
Prostate carcinoma,
Sildenafil,
Tadalafil
Related subjects:
Medicine,
Clinical medicine,
Clinical medicine, other

© 2022 Dejan Simic, Aleksandar Spasic, Mirko Jovanovic, Predrag Maric, Radovan Milosevic, Ivan Srejovic, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 23 (2022): Issue 2 (June 2022)Next article